Study of hsCRP, adiponectin, NF-κB in low bodyweight, standard bodyweight and obese subjects with type 2 diabetes mellitus in India

Sidhartha Das, Durga Prasanna Misra, Pratima Kumari Sahu

Department of Biochemistry, Sriram Chandra Bhanj Medical College, Cuttack, India.
Department of Medicine, Sriram Chandra Bhanj Medical College, Cuttack, India.

DOI: 10.4236/jdm.2012.24060                

Abstract

Introduction: Low bodyweight type 2 DM is a distinct clinical entity having many inherent peculiarities seen in India and developing countries, constituting 11% to 25% of type 2 diabetic subjects. Our study aimed at assessing the prevalence of inflammatory markers like hsCRP, adiponectin and NF-κB expression in peripheral blood mononuclear cells in subjects with type 2 DM in relation to BMI. Materials and Methods: 57 consecutive type 2 diabetics were recruited for study, classified as Low Bodyweight (A = BMI < 18.5), Standard weight (B = BMI 18.5 - 24.99) and Obese (C = BMI ≥ 25). Group D comprised 14 healthy controls. They were evaluated for clinical parameters, FBG, 2hrPPBG, HbA1c, lipid profile and above mentioned inflammatory markers. Results: Serum hsCRP was significantly higher in all group of diabetics as compared to Group D but was lowest in Group A. Adiponectin levels were highest in Group D, similar in Groups B and C but lowest in Group A. NF-κB expression, though higher in diabetic subjects than controls (OD = 0.041 ± 0.006), was least in Group A (OD = 0.045 ± 0.005). Discussion and Conclusion: Our study revealed that Indians with type 2DM are in a pro-inflamematory state. Low bodyweight type 2 diabetics had the least pro-inflammatory load. This further supported the earlier observation of lesser macrovascular disease load and testifying that Low Bodyweight type2DM constitutes a distinct entity.

Keywords

Low Bodyweight Type 2 DM; hsCRP; NF-κB; Adiponectin

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Das, S. and Fonseca, V. (2009) Low bodyweight type 2 diabetes in India: Clinical characteristics and pathophysiology. Diabetes & Metabolic Syndrome: Clinical Research and Reviews, 3, 60-66. doi:10.1016/j.dsx.2009.01.001
[2]	Diamond, J. (2011) Diabetes in India. Nature, 469, 478-479. doi:10.1038/469478a
[3]	Tripathy, B.B. and Rao, H. (1996) Malnutrition and diabetes in the tropics. Report of the international workshop on types of diabetes peculiar to the tropics. Diabetes Care, 19, 1014-1017.
[4]	Pickup, J.C. (2004) Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care, 27, 813-823. doi:10.2337/diacare.27.3.813
[5]	Dandona, P., Aljada, A., Chaudhuri, A., Mohanty, P. and Garg, R. (2005) Metabolic syndrome: A comprehensive perspective based on interaction between obesity, diabetes and inflammation. Circulation, 111, 1448-1454. doi:10.1161/01.CIR.0000158483.13093.9D
[6]	Ziemke, F. and Mantzoros, C.S. (2010) Adiponectin in insulin resistance: Lessons from translational research. The American Journal of Clinical Nutrition, 91, 258S-261S. doi:10.3945/ajcn.2009.28449C
[7]	Kawano, J. and Arora, R. (2009) The role of adiponectin in obesity, diabetes and cardiovascular disease. Journal of the CardioMetabolic Syndrome, 4, 44-49. doi:10.1111/j.1559-4572.2008.00030.x
[8]	Gustafson, B. (2010) Adipose tissue, inflammation and atherosclerosis. Journal of Atherosclerosis and Thrombosis, 17, 332-341. doi:10.5551/jat.3939
[9]	Natarajan, R. and Nadler, J.L. (2004) Lipid inflammatory mediators in diabetic vascular disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 24, 1542-1548. doi:10.1161/01.ATV.0000133606.69732.4c
[10]	Das, S. (1994) Identity of lean-NIDDM: Clinical, metabolic and hormonal status. In: Kochupillai, N., Ed., Advances in Endocrinology Metabolism and Diabetes, Vol. 2, Macmillan, Delhi, 42-53.
[11]	Das, S., Samal, K.C. and Baliarsinha, A.K. (1995) Lean (underweight) NIDDM-peculiarities and differences in metabolic and hormonal status. JR Assn Phys Ind, 43, 339-342.
[12]	Das, S. (1999) low bodyweight type 2 diabetes mellitus, technical series. Indian College of Physicians (ICP), Academic Wing of Association of Physicians of India, Mumbai.
[13]	Zimmet, P.Z., Tuomi, T., Mackay, I.R., Rowley, M.J., Knowles, W., Cohen, M. and Lang, A. (1994) Latent autoimmune diabetes mellitus in adults (LADA): The role of anti-bodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabetic Medicine, 11, 299-303. doi:10.1111/j.1464-5491.1994.tb00275.x
[14]	Mohan, V., Vijayaprabha, R., Rema, M., Premlatha, G., Poongothai, S., Deepa, B.E., Mackay, I.R. and Zimmet, P. (1997) Clinical profile of lean NIDDM in South India. Diabetes Research and Clinical Practice, 38, 101-108. doi:10.1016/S0168-8227(97)00088-0
[15]	Das, S., Bhoi, S.K., Baliarsinha, A.K. and Baig, M.A. (2007) Autoimmunity, insulin resistance and beta cell function in subjects with low body weight type 2 diabetes mellitus. Metabolic Syndrome and Related Disorders, 5, 136-141.
[16]	Das, S., Reynolds, T., Patnaik, A., Rais, N., Fink, L.M. and Fonseca, V.A. (1999) Plasma homocysteine concentrations in type 2 diabetics in India: Relationship to body-weight. Journal of Diabetes and Its Complications, 13, 200-203. doi:10.1016/S1056-8727(99)00045-8
[17]	Lannergard, A., Friman, G., Ewald, U., Lind, L. and Larsson, A. (2005) Serum amyloid A (SAA) protein and high-sensitivity Creactive protein (hsCRP) in healthy newborn infants and healthy young through elderly adults. Acta Paediatrica, 94, 1198-1202. doi:10.1111/j.1651-2227.2005.tb02074.x
[18]	Devaraj, S., Valleggi, S., Siegel, D. and Jialal, I. (2010) Role of C-reactive protein in contributing to increased cardiovascular risk in metabolic syndrome. Current Atherosclerosis Reports, 12, 110-118. doi:10.1007/s11883-010-0098-3
[19]	Pickup, J.C. and Crook, M.A. (1998) Is type II diabetes mellitus a disease of the innate immune system? Diabetologia, 41, 1241-1248. doi:10.1007/s001250051058
[20]	Dhindsa, S., Tripathy, D., Mohanty, P., Ghanim, H., Syed, T., Aljada, A. and Dandona, P. (2004) Differential effects of glucose and alcohol on reactive oxygen species generation and intranuclear factor—kappaB in mononuclear cells. Metabolism, 53, 330-334. doi:10.1016/j.metabol.2003.10.013
[21]	Hofmann, M.A., Schiekofer, S., Kanitz, M., Klevesath, M.S., Joswig, M., Lee, V., et al. (1998) Insufficient glycemic control increases nuclear factor-kappa B binding activity in peripheral blood mononuclear cells isolated from patients with type 1 diabetes. Diabetes Care, 21, 1310-1316. doi:10.2337/diacare.21.8.1310
[22]	Patnaik, A., Das, S. and Patnaik, B. (1999) Hepatic metabolic states and glucokinase. In: Das, S., Ed., Low Bodyweight Type 2 Diabetes Mellitus, Association of Physicians of India, Mumbai, 48-53.
[23]	Das, S. and Sotaniemi, E.A. (1999) Hepatic microsomal enzymes and Cyto P450 activity. In: Das, S., Ed., Technical Series on “Low Bodyweight Type 2 Diabetes Mellitus”, Indian College of Physicians (Academic Wing of Association of Physicians of India), Mumbai, 54-58.